NewAmsterdam Pharma Announces Participation in Key Investor Conferences
![NewAmsterdam Pharma Announces Participation in Key Investor Conferences](https://investorshangout.com/images/blog/ihnews-NewAmsterdam%20Pharma%20Announces%20Participation%20in%20Key%20Investor%20Conferences.jpg)
NewAmsterdam Pharma to Attend Investor Conferences
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a prominent biopharmaceutical company, is dedicated to developing innovative oral medicines that aim to lower low-density lipoprotein cholesterol levels for those at risk of cardiovascular disease (CVD). The company is gearing up for an upcoming series of investor conferences where management will discuss their latest developments and future plans.
Upcoming Conferences
Company representatives are slated to participate in major industry events where they will engage directly with investors and share insights into their exciting pipeline:
- Morgan Stanley 22nd Annual Global Healthcare Conference. This event will take place in New York City. On September 5, company management will host one-on-one meetings, followed by a key presentation from Ian Somaiya, the Chief Financial Officer, on September 6 at 10:00 a.m. ET.
- Cantor Global Healthcare Conference. Scheduled for September 17, Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya will join a fireside chat at 3:40 p.m. ET.
These events will provide valuable opportunities for investors to learn more about NewAmsterdam's strategic direction, particularly in addressing unmet medical needs in the CVD therapeutic landscape.
Webcasts Available
For those unable to attend the conferences in person, live webcasts of the presentations will be accessible through the investor relations section of the NewAmsterdam Pharma website. After the events, archived recordings will also be available for review, ensuring that all interested parties can catch up on the discussions that took place.
About NewAmsterdam Pharma
NewAmsterdam Pharma (Nasdaq: NAMS) is at the forefront of developing therapies for metabolic diseases where existing treatments are lacking. Their mission entails providing effective, safe, and easily tolerable medication aimed at lowering LDL cholesterol levels.
Currently, the company is conducting multiple phase 3 studies on obicetrapib. This oral, low-dose CETP inhibitor is designed to be taken once daily and can be utilized as a complementary therapy alongside statins for patients who do not adequately respond to standard treatments.
Company Contact Information
For more information, Matthew Philippe can be reached at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.
Contact for Media and Investor Relations
Media inquiries should be directed to Bryan Blatstein at Spectrum Science. He can be contacted at 1-917-714-2609 or via email at bblatstein@spectrumscience.com. For investor relations, reach out to Austin Murtagh at 1-212-698-8696 or austin.murtagh@precisionaq.com.
Frequently Asked Questions
What is NewAmsterdam Pharma known for?
NewAmsterdam Pharma focuses on developing oral, non-statin therapies aimed at lowering LDL cholesterol for patients at risk of cardiovascular disease.
What conferences will NewAmsterdam attend?
The company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference.
What is the significance of these conferences?
These conferences allow management to showcase their advancements and engage with investors regarding the company’s strategies and pipeline.
How can I access the conference presentations?
Live webcasts of the presentations will be available on NewAmsterdam's investor relations website, with archived versions provided later.
Who can I contact for more information about NewAmsterdam?
You can reach Matthew Philippe for inquiries or for more details about the company's initiatives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global Fermenters Market Growth Dynamics and Insights
- Coloplast A/S: Trading Updates from Board Members
- GVRenting Champions Urban Sustainability Initiatives
- US Stocks Surge with Positive Inflation News
- Jostens Partners with West Point for 2026 Class Rings
- Exploring the Growth of the Powder Coatings Market
- Clarification on Fintech360 and Nuvei Collaboration
- Hudbay's Copper World Project Secures Key Permit for Growth
- Public Disclosure of Interests in Balanced Commercial Property Trust
- Keyword Studios Plc: Recent Disclosures by Rathbones Group
- Rivian to Showcase Innovations at Goldman Sachs Conference
- Atlantic Petroleum Reports Q2 2024 Financial Results
- Penetration Testing Market Growth Driven by Cyber Threats
- Lubricating Oil Additives Market to Hit $25.66 Billion
- Intelligent Vending Machines Market Growth Predictions
- Artificial Intelligence in Healthcare Market Growth Insights
- Baby Drinks Market Set to Reach $109.66 Billion Soon
- AmpliTech Group Achieves Over $1M in August Bookings
- MoneyHero Group to Release Q2 2024 Financial Results
- Scilex Holding Company to Showcase ZTlido at PAINWeek
- Albion KAY VCT PLC Announces Voting Rights Update
- Albion Technology & General VCT PLC Voting Rights Update
- Albion Development VCT PLC Voting Rights Update
- Albion Venture Capital Trust Voting Rights Update
- Albion Crown VCT Announces Total Voting Rights and Capital
Recent Articles
- Next Generation Cancer Diagnostics Market Insights
- Emergent BioSolutions Launches Ready to Rescue Initiative
- Mulvihill U.S. Health Care Enhanced Yield ETF Reports Results
- Innofactor Plc Manager's Transactions: Martin Söderlind
- Passage Bio to Showcase Innovations at Annual Conference
- Latest Voting Rights Update for Northern 2 VCT PLC
- European Stock Market Trends and Economic Outlook
- Bayport Management Ltd Announces Important Transaction Details
- Emergent BioSolutions Approved ACAM2000® for Mpox
- LNG Energy Group Announces Strong Q2 2024 Results
- Solar Alliance Reports Profitable First Half Results
- NVIDIA Schedules Event for Financial Community Engagement
- Intel Stock Gains Amidst AI Market Trends
- Shell plc Announces Share Buyback Program
- WGU Labs and CodeSignal Collaboration to Enhance Job Readiness
- Jøtul Group Reports Significant Revenue Decline in H1 2024
- Enstar Finalizes Strategic Transaction with IAG
- Nvidia's Future: Analyzing AI Leadership and Stock Potential
- Ethos $ETHOS Token Launch: Exclusive Early Incentives
- Air Conditioning System Market Set for Significant Growth
- Vericel Corporation's Upcoming Presentation at Healthcare Conference
- Fazoli’s Expands Its Footprint with New Location in Georgia
- AgEagle Aerial Systems Participates in Collaborative Flight Event
- U.S. Economic Growth Shows Resilience Amid Challenges
- Walgreens Boots Alliance at Risk of Dividend Cuts